Network News

Got a startup idea? Curious about entrepreneurship? Then the GeneNovate program is the perfect place to start! Objective GeneNovate is the first nationwide entrepreneurship program in Germany, designed to empower innovators and entrepreneurs in the field of Gene and Cell Therapies (GCT), Biotech and Medicine. The program targets early-career scientists and physicians, such as advanced […]

Chicago, IL – October 8th, 2025 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now published on BioRxiv. Plasmids have long been a key material […]

October 7, 2025 Celonic Group one of the leading “pureplay” Biologics CDMO, and The Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution. The alliance combines Celonic’s advanced biologics capabilities with CARBOGEN […]

Chicago, IL – SEPTEMBER 30th, 2025 – VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene Therapy Excellence Awards 2025 (APCGTEA) and the Asia-Pacific Biologics CDMO Excellence Awards 2025 (APBCEA), hosted by IMAPAC. ● Best Cell & Gene Therapy Supplier Award – AAV Vector Manufacturing ● Best Gene […]

Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the initiation of Cohort 9 in its ongoing Phase I/IIa dose escalation trial of HDP-101, the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma. The Safety Review Committee […]

Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today resolved with the approval of the Supervisory Board to implement extensive cost-saving measures and consequently, to focus all development activities exclusively on lead ADC candidate HDP-101 to extend the Company’s cash reach. This […]

The partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases. ZURICH,SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 — VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH,“Voyager”), and Secarna Pharmaceuticals GmbH & Co. KG, a company […]

Prestigious award for the developer of the first approved drug against hepatitis D On September 18, Prof. Dr. Dr. h.c. Stephan Urban, DZIF Professor of Translational Virology at Heidelberg University’s Medical Faculty, was honored with the McGuigan Award for Distinguished Work in Drug Discovery. The prize, worth £10,000, recognizes Urban’s outstanding scientific achievement and the […]

First pivotal Phase III study exPDite-2 for allogeneic pluripotent stem cell therapy Bemdaneprocel initiated / Phase II gene therapy study REGENERATE-PD with AB-1005 initiated in the United Kingdom and Poland, Germany to follow soon and continuing in the US / Parkinson’s disease is the second most common and fastest growing neurodegenerative disease, affecting more than […]